PSP Research’s Ionis Pharmaceuticals IONS Stock Holding History

PSP Research’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$539K	Hold	6,800	–	–	0.29%	14
2026 Q1	$511K	Hold	6,800	–	–	0.36%	14
2025 Q4	$538K	Buy	+6,800	New	+$512K	0.47%	25

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

PSP Research's IONS Position: Q2 2026 in Review

PSP Research held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 6,800 shares worth $539K. The position accounts for 0.29% of the portfolio, ranked #14.

PSP Research first reported a position in IONS in Q4 2025 and has held it in 3 quarters since. 512 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

PSP Research held 6,800 shares of Ionis Pharmaceuticals worth $539K as of Q2 2026.
PSP Research left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
Ionis Pharmaceuticals made up 0.29% of PSP Research's portfolio in Q2 2026, its #14 holding.
PSP Research first reported a position in Ionis Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
512 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.